Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 ...

Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

Shares in Pfizer ($PFE) inched higher early Tuesday even as the U.S. pharma giant forecast 2026 earnings that are below Wall ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results ...

Pfizer (NYSE:PFE) shares slid about 3% on Tuesday morning after the company lowered its earnings and revenue forecasts for ...

Pfizer (PFE) stock is in focus as the firm's revised 2025 revenue outlook and its 2026 earnings outlook miss the consensus.

As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a ...

Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.

The big drugmaker should be even bigger over the next five years despite facing a patent cliff. It's a different story today. Sales for Pfizer's COVID-19 vaccine have declined significantly. The ...

J&J believes 10 of its new products/pipeline candidates in the Innovative Medicine segment have the potential to deliver peak ...